Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel Marty Pyke

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
BMC Medical Genomics|July 27, 2019
Elevated neoantigen levels in tumors with somatic mutations in the HLA-A, HLA-B, HLA-C and B2M genesAndrea Castro, Kivilcim Ozturk, Rachel Marty Pyke, et al.
Cell|September 25, 2018
Evolutionary Pressure against MHC Class II Binding Cancer MutationsRachel Marty Pyke, Wesley Kurt Thompson, Rany M Salem, et al.
Nature Communications|August 19, 2020
Strength of immune selection in tumors varies with sex and ageAndrea Castro, Rachel Marty Pyke, Xinlian Zhang, et al.
Genome Medicine|May 21, 2020
MHC-I genotype and tumor mutational burden predict response to immunotherapyAaron M Goodman, Andrea Castro, Rachel Marty Pyke, et al.
Molecular & Cellular Proteomics : MCP|February 16, 2023
Precision Neoantigen Discovery Using Large-Scale Immunopeptidomes and Composite Modeling of MHC Peptide PresentationRachel Marty Pyke, Datta Mellacheruvu, Steven Dea, et al.
Nature Communications|April 13, 2022
A machine learning algorithm with subclonal sensitivity reveals widespread pan-cancer human leukocyte antigen loss of heterozygosityRachel Marty Pyke, Dattatreya Mellacheruvu, Steven Dea, et al.
Molecular & Cellular Proteomics : MCP|June 14, 2021
Withdrawn: Precision Neoantigen Discovery Using Large-scale Immunopeptidomes and Composite Modeling of MHC Peptide PresentationRachel Marty Pyke, Dattatreya Mellacheruvu, Steven Dea, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2021
Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance MechanismsCharles W Abbott, Sean M Boyle, Rachel Marty Pyke, et al.
Oncotarget|March 14, 2024
Analytical validation of NeXT Personal®, an ultra-sensitive personalized circulating tumor DNA assayJosette Northcott, Gabor Bartha, Jason Harris, et al.
Nature Medicine|January 13, 2025
Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinomaJames R M Black, Gabor Bartha, Charles W Abbott, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
BMC Medical Genomics|July 27, 2019
Elevated neoantigen levels in tumors with somatic mutations in the HLA-A, HLA-B, HLA-C and B2M genesAndrea Castro, Kivilcim Ozturk, Rachel Marty Pyke, et al.
Cell|September 25, 2018
Evolutionary Pressure against MHC Class II Binding Cancer MutationsRachel Marty Pyke, Wesley Kurt Thompson, Rany M Salem, et al.
Nature Communications|August 19, 2020
Strength of immune selection in tumors varies with sex and ageAndrea Castro, Rachel Marty Pyke, Xinlian Zhang, et al.
Genome Medicine|May 21, 2020
MHC-I genotype and tumor mutational burden predict response to immunotherapyAaron M Goodman, Andrea Castro, Rachel Marty Pyke, et al.
Molecular & Cellular Proteomics : MCP|February 16, 2023
Precision Neoantigen Discovery Using Large-Scale Immunopeptidomes and Composite Modeling of MHC Peptide PresentationRachel Marty Pyke, Datta Mellacheruvu, Steven Dea, et al.
Nature Communications|April 13, 2022
A machine learning algorithm with subclonal sensitivity reveals widespread pan-cancer human leukocyte antigen loss of heterozygosityRachel Marty Pyke, Dattatreya Mellacheruvu, Steven Dea, et al.
Molecular & Cellular Proteomics : MCP|June 14, 2021
Withdrawn: Precision Neoantigen Discovery Using Large-scale Immunopeptidomes and Composite Modeling of MHC Peptide PresentationRachel Marty Pyke, Dattatreya Mellacheruvu, Steven Dea, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2021
Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance MechanismsCharles W Abbott, Sean M Boyle, Rachel Marty Pyke, et al.
Oncotarget|March 14, 2024
Analytical validation of NeXT Personal®, an ultra-sensitive personalized circulating tumor DNA assayJosette Northcott, Gabor Bartha, Jason Harris, et al.
Nature Medicine|January 13, 2025
Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinomaJames R M Black, Gabor Bartha, Charles W Abbott, et al.
Pageof 2